Robert LeBoyer
Stock Analyst at Noble Financial
(0.05)
# 4,437
Out of 4,463 analysts
412
Total ratings
29.1%
Success rate
-10.2%
Average return
Main Sectors:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRSN NeuroSense Therapeutics | Reiterated: Buy | $9 | $0.73 | +1,132.88% | 7 | Jul 2, 2026 | |
| UNCY Unicycive Therapeutics | Reiterated: Buy | $60 → $50 | $5.55 | +800.90% | 19 | Jul 1, 2026 | |
| ELDN Eledon Pharmaceuticals | Reiterated: Buy | $10 | $3.94 | +154.13% | 21 | Jun 23, 2026 | |
| MAIA MAIA Biotechnology | Reiterated: Buy | $14 | $1.47 | +855.63% | 22 | Jun 22, 2026 | |
| CVKD Cadrenal Therapeutics | Reiterated: Buy | $45 | $2.95 | +1,425.42% | 16 | Jun 16, 2026 | |
| GLSI Greenwich LifeSciences | Reiterated: Buy | $45 | $23.37 | +92.59% | 9 | Jun 2, 2026 | |
| GOVX GeoVax Labs | Reiterated: Buy | $10 | $1.26 | +693.65% | 25 | May 27, 2026 | |
| COCP Cocrystal Pharma | Reiterated: Buy | $6 → $10 | $1.02 | +880.39% | 28 | May 27, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Buy | $12 | $1.30 | +823.08% | 5 | May 22, 2026 | |
| GYRE Gyre Therapeutics | Reiterated: Buy | $20 | $6.52 | +206.75% | 10 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $5.53 | +44.67% | 7 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $1.53 | +686.89% | 41 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.09 | +385.44% | 9 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $37 | $12.68 | +191.80% | 30 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.10 | n/a | 5 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8222 | n/a | 24 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8732 | n/a | 36 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.16 | n/a | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.53 | n/a | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $9 | $1.31 | n/a | 11 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $0.73 | $0.135 | n/a | 2 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $20 | $2.62 | n/a | 10 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $27 | $0.0001 | n/a | 7 | Feb 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $15 | $4.75 | n/a | 8 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $4.01 | n/a | 1 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $14 | $1.42 | n/a | 7 | Jan 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.68 | n/a | 2 | Dec 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $1.52 | n/a | 6 | Dec 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.0001 | n/a | 5 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $12.69 | n/a | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $3.04 | n/a | 8 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $1.46 | n/a | 1 | Feb 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.23 | n/a | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.94 | n/a | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $17 → $1 | $35.38 | n/a | 2 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.36 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 4 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.19 | n/a | 3 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.6301 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.22 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.49 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $54 → $41 | $25.34 | n/a | 2 | Aug 5, 2016 |
NeuroSense Therapeutics
Jul 2, 2026
Reiterated: Buy
Price Target: $9
Current: $0.73
Upside: +1,132.88%
Unicycive Therapeutics
Jul 1, 2026
Reiterated: Buy
Price Target: $60 → $50
Current: $5.55
Upside: +800.90%
Eledon Pharmaceuticals
Jun 23, 2026
Reiterated: Buy
Price Target: $10
Current: $3.94
Upside: +154.13%
MAIA Biotechnology
Jun 22, 2026
Reiterated: Buy
Price Target: $14
Current: $1.47
Upside: +855.63%
Cadrenal Therapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $45
Current: $2.95
Upside: +1,425.42%
Greenwich LifeSciences
Jun 2, 2026
Reiterated: Buy
Price Target: $45
Current: $23.37
Upside: +92.59%
GeoVax Labs
May 27, 2026
Reiterated: Buy
Price Target: $10
Current: $1.26
Upside: +693.65%
Cocrystal Pharma
May 27, 2026
Reiterated: Buy
Price Target: $6 → $10
Current: $1.02
Upside: +880.39%
Cardiff Oncology
May 22, 2026
Reiterated: Buy
Price Target: $12
Current: $1.30
Upside: +823.08%
Gyre Therapeutics
May 8, 2026
Reiterated: Buy
Price Target: $20
Current: $6.52
Upside: +206.75%
May 8, 2026
Reiterated: Buy
Price Target: $8
Current: $5.53
Upside: +44.67%
May 6, 2026
Reiterated: Buy
Price Target: $12
Current: $1.53
Upside: +686.89%
Apr 6, 2026
Reiterated: Buy
Price Target: $15
Current: $3.09
Upside: +385.44%
Mar 16, 2026
Reiterated: Buy
Price Target: $70 → $37
Current: $12.68
Upside: +191.80%
Jun 27, 2025
Rated: Hold
Price Target: n/a
Current: $0.10
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $0.8222
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $0.8732
Upside: n/a
Jan 21, 2025
Rated: Hold
Price Target: n/a
Current: $0.16
Upside: n/a
Aug 16, 2022
Reiterated: Buy
Price Target: $5
Current: $0.53
Upside: n/a
Aug 15, 2022
Reiterated: Buy
Price Target: $8 → $9
Current: $1.31
Upside: n/a
Jun 1, 2022
Reiterated: Buy
Price Target: $0.73
Current: $0.135
Upside: n/a
May 14, 2021
Maintained: Buy
Price Target: $20 → $20
Current: $2.62
Upside: n/a
Feb 9, 2021
Maintained: Buy
Price Target: $18 → $27
Current: $0.0001
Upside: n/a
Jan 26, 2021
Maintained: Buy
Price Target: $6 → $15
Current: $4.75
Upside: n/a
Jan 25, 2021
Initiated Coverage: Buy
Price Target: $8
Current: $4.01
Upside: n/a
Jan 24, 2021
Maintained: Buy
Price Target: $6 → $14
Current: $1.42
Upside: n/a
Dec 28, 2020
Downgraded: Hold
Price Target: n/a
Current: $4.68
Upside: n/a
Dec 24, 2020
Maintained: Buy
Price Target: $6
Current: $1.52
Upside: n/a
Nov 12, 2020
Reiterated: Buy
Price Target: $8
Current: $0.0001
Upside: n/a
Oct 5, 2020
Downgraded: Hold
Price Target: n/a
Current: $12.69
Upside: n/a
May 28, 2020
Maintained: Buy
Price Target: $5
Current: $3.04
Upside: n/a
Feb 18, 2020
Initiated Coverage: Buy
Price Target: $30
Current: $1.46
Upside: n/a
Nov 1, 2018
Rated: Hold
Price Target: n/a
Current: $4.23
Upside: n/a
Nov 1, 2018
Rated: Hold
Price Target: n/a
Current: $2.94
Upside: n/a
Apr 10, 2018
Downgraded: Hold
Price Target: $17 → $1
Current: $35.38
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $3.36
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $9.19
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $0.6301
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $1.22
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $2.49
Upside: n/a
Aug 5, 2016
Downgraded: Hold
Price Target: $54 → $41
Current: $25.34
Upside: n/a